Sign in

Peter Kolchinsky

@peterkolchinsky.bsky.social
783 followers 27 following 64 posts

Biotech investor. Virologist. Author: The Great American Drug Deal. Founder: No Patient Left Behind. Healthcare reform advocate. Daughter says I’m cool 75% of the time; son says 100%.

PostsRepliesMedia
Reposted by Peter Kolchinsky
Holly Fernandez Lynch @hollylynchez.bsky.social · 07/12/2025
Here, here. "Congress must now also exercise its oversight responsibilities to ensure repairs to FDAs current and future capabilities, infrastructure, human resources, and reputation begin as soon as possible." Big deal coming from investors/companies. www.nopatientleftbehind.org/evidence-bas...
nopatientleftbehind.org
Supporting the Call for Evidence-Based Policy and Public Health Security — No Patient Left Behind
095
Reposted by Peter Kolchinsky
No Patient Left Behind @nplb.bsky.social · 04/03/2025
Autoimmune diseases afflict 45 million Americans—and it requires a collective community effort to change that. Our new Community Quest video shows how investors, innovators, regulators, patients, insurers—and you—make new treatments possible, accessible, and affordable.
nopatientleftbehind.org
Our Quest to Beat Autoimmune Disorders — No Patient Left Behind
Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.
185
Peter Kolchinsky @peterkolchinsky.bsky.social · 22/02/2025
Anyone with questions about drug pricing, investment in innovation, insurance… There is now an AI you can speak with: www.nopatientleftbehind.org/chat-nplb Give it a spin. Call out what you think it gets wrong. (That’s one of the exercises in the NPLB fellowship, actually).
nopatientleftbehind.org
chat-NPLB — No Patient Left Behind
020
Peter Kolchinsky @peterkolchinsky.bsky.social · 17/02/2025
No Patient Left Behind steps up again @nplb.bsky.social Video from many #biotech leaders to #Trump on addressing international freeriding (others paying less than US for meds). Learn why “Most Favored Nation” policy backfires… and a better approach. www.nopatientleftbehind.org/protect-amer...
nopatientleftbehind.org
Protect American Innovation — No Patient Left Behind
040
Peter Kolchinsky @peterkolchinsky.bsky.social · 25/01/2025
Do you serve on a biotech board? Wish meetings were clearer, shorter, focused on strategy? You’ll love RA Capital’s Gateway (gateway.racap.com), a resource for execs/directors. Insights from peers. Used by thousands. Eg. Core value propositions & elephant slides. Role of chair. Price discovery
gateway.racap.com
021
Peter Kolchinsky @peterkolchinsky.bsky.social · 25/01/2025
Rfk Jr & vaccine “skeptics” mislead when they say vaccines haven’t been tested vs placebo. The first vaccine of every kind is absolutely tested vs placebo. When it works, it’s unethical to test future versions vs placebo. Those are tested vs prior version. If better, then also better than placebo.
082
Peter Kolchinsky @peterkolchinsky.bsky.social · 21/01/2025
Reposting for the Harvard Biotech Club members who are joining now for the podcast recording.
050
Peter Kolchinsky @peterkolchinsky.bsky.social · 15/01/2025
Flying back from JPM? Watch this. Congressman Jake Auchincloss knows more about what’s wrong with healthcare, PBMs, drug value assessment, & pricing policy than most executives. Biocentury’s @steveusdin.bsky.social interview surfaces issues all execs need to know. www.youtube.com/watch?v=w-Ji...
youtube.com
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
YouTube video by BioCentury Video
140
Peter Kolchinsky @peterkolchinsky.bsky.social · 11/01/2025
Biotech on Bluesky get a look first. RA Capital’s annual thoughts on how biotech can better (Semper Maior; always better). This one explore how we can elicit more candor. Some stories, too. And tons of top-down data analyzing 2024 performance & setup for 2025. rapport.bio/all-stories/...
rapport.bio
Semper Maior: Pumping up the candor — RApport
Wouldn’t it be better if everyone in our ecosystem were candid with one another? After all, within companies it’s common to encourage everyone to speak their minds. If you see a problem, call it out;...
0133
Peter Kolchinsky @peterkolchinsky.bsky.social · 08/01/2025
Biotech on Bluesky, I’m sharing with you first. RA Capital just launched Biotech Unveiled, a free online course our team created. Learn at own pace. Covers fundamentals of how insurance + investment direct R&D. Essential knowledge for leaders. racap.thinkific.com/courses/biot...
racap.thinkific.com
Biotech Unveiled: How the Biotech Industry Works
Designed to empower biotech professionals early in their career and set them up to succeed in the broader context in which they operate, this free mini-course is full of everything you've wanted to know about biotech but didn't know who to ask.
34213
Peter Kolchinsky @peterkolchinsky.bsky.social · 04/01/2025
The interesting thing about Bluesky is watching something like the Wild West open up. Who knows if it ever becomes as populated as Twitter, but in these early days, you see how a platform takes shape. For example, notice the ratio of followers to posts… it seems a sign of how… 1/4
110
Peter Kolchinsky @peterkolchinsky.bsky.social · 03/01/2025
As a virologist, I encourage everyone to listen to @scottgottliebmd.bsky.social’s advice on preparing for possible flu pandemic. As an investor, I hope US makes appropriate investments. We have better tools now than we did for COVID. Diff virus, diff tools. www.washingtonpost.com/opinions/202...
washingtonpost.com
Opinion | Biden faltered on bird flu. Here’s how Trump can course-correct.
The Biden administration’s bird flu response has been too slow. Now comes a test for Trump’s White House.
040
Peter Kolchinsky @peterkolchinsky.bsky.social · 02/01/2025
My whole career (scientist/VC) there were diseases that I thought I might never be cracked. Alzheimer’s was one. Now seeing signs of progress. Lupus was another, now cracking. I think it’s curable. What diseases would you want to see cured? Scientists here can add if they feel optimistic.
200
Peter Kolchinsky @peterkolchinsky.bsky.social · 29/12/2024
What was an investor’s real reason for passing? What do they know? Might that info help a company? Yet, there’s a downside to candor. Feelings may get hurt. Investors get ghosted on deal. How might we flip it so there’s upside? Insights from #biotech & any sector welcome.
141
Peter Kolchinsky @peterkolchinsky.bsky.social · 24/12/2024
Every Xmas, those of us who are w/ our families appreciate all who work to keep the world running. Store clerks, nurses, police, public utility workers… …and, did you know, in the drug industry, many scientists & technicians keep experiments running & medicines in production. Thank you all :)
090
Peter Kolchinsky @peterkolchinsky.bsky.social · 19/12/2024
I’m involved with No Patient Left Behind’s fellowship program www.nopatientleftbehind.org When students ask me for career advice, I often share the same stories & suggestions. Here’s what I say. (This is long)…
nopatientleftbehind.org
No Patient Left Behind
3271
Reposted by Peter Kolchinsky
Nivedita Sarveswaran @neuroniv.bsky.social · 02/12/2024
Super informative article from @peterkolchinsky.bsky.social covering the health economics of Vertex’s Nav1.8 inhibitor VX-548/suzetrigine rapport.bio/all-stories/...
rapport.bio
Managing pain without opioids is on the horizon – if we decide it’s worth it — RApport
Thanks to the relentless efforts of scientists at Vertex Pharmaceuticals, there will likely soon be a novel non-opioid pain medicine. How insurance plans, including Medicare, decide to cover this drug...
243
Peter Kolchinsky @peterkolchinsky.bsky.social · 30/11/2024
Love my bookshop; take my kids there to buy books b/c great experience. If it weren’t, I wouldn’t support just to keep them employed. Amazon is great, too (covid!). Even if it displaced bookshops, people would do something else society valued. Imagine shunning cars to support carriage drivers.
010
Peter Kolchinsky @peterkolchinsky.bsky.social · 27/11/2024
Healthcare costs are high, but there's an 8% slice that does more than anything to improve our lives & drive down costs. If drug prices come up during TG dinner, you’ll win w/these points ;) @phrma.bsky.social @naturebiotech.bsky.social #biotech @nplb.bsky.social rapport.bio/all-stories/...
rapport.bio
A lot for a little: The best 8% slice of our healthcare dollar — RApport
Unlike our healthcare spending that goes to services and should be considered an expense, the mere 8% we spend on novel medicines doesn’t just pay for the same things year over year – it’s an investme...
1123